Lessor R A, Bajwa B S, Rice K C, Jacobson A E, Streaty R A, Klee W A, Smith C B, Aceto M D, May E L, Harris L S
J Med Chem. 1986 Nov;29(11):2136-41. doi: 10.1021/jm00161a002.
N-Allyl-, N-(cyclopropylmethyl)-, and N-propyl-endo-ethenotetrahydronororipavines (N-substituted 6,14-endo-etheno-4,5-epoxy-3-hydroxy-6-methoxymorphinans) were synthesized with potential acylating or alkylating moieties at the C-7 position (isothiocyanato, (bromoacetyl)amino, and (methoxyfumaroyl)amino) and examined in vivo for their narcotic agonist and antagonist activities and for their ability to interact with opioid receptors in vitro. The N-(cyclopropylmethyl)-substituted compounds were found to have the highest affinity for opioid receptors among these N-substituted compounds, although all of them were found to be reasonably potent narcotic antagonists in the mouse tail flick vs. morphine assay. Their in vivo potency ranged from 1/8 to 4 times that of nalorphine on intravenous injection in mice. Rat brain membrane binding studies indicated that the compounds interacted with opioid receptors with potencies that ranged from 0.5 times that of morphine (8c, 9c, and 10c) to 0.017 that of morphine (8b). Among the compounds studied here, only the previously reported isothiocyanato compound (10c) and (methoxyfumaroyl)amino compound (8c) interacted irreversibly and selectively with mu or delta opioid receptors, respectively, in assays using NG108-15 neuroblastoma-glioma hybrid cells and/or in a rat brain membrane preparation. Both 8c and 10c were found to interact irreversibly, to a limited extent, with kappa opioid sites in rat brain membranes in which the mu and delta opioid receptors were depleted by interaction with the mu-selective irreversible ligand BIT and the delta-selective irreversible ligand FIT. Neither compound showed irreversible actions in the electrically stimulated mouse vas deferens preparation.
合成了N-烯丙基-、N-(环丙基甲基)-和N-丙基-内-乙烯基四氢去甲奥里派文(N-取代的6,14-内-乙烯基-4,5-环氧-3-羟基-6-甲氧基吗啡喃),其在C-7位带有潜在的酰化或烷基化基团(异硫氰酸根合、(溴乙酰基)氨基和(甲氧基富马酰基)氨基),并在体内检测其麻醉激动剂和拮抗剂活性以及在体外与阿片受体相互作用的能力。发现这些N-取代化合物中,N-(环丙基甲基)-取代的化合物对阿片受体具有最高亲和力,尽管在小鼠甩尾对抗吗啡试验中发现它们都是相当有效的麻醉拮抗剂。它们的体内效价在小鼠静脉注射时为纳洛啡的1/8至4倍。大鼠脑膜结合研究表明,这些化合物与阿片受体相互作用的效价范围从吗啡的0.5倍(8c、9c和10c)到吗啡的0.017倍(8b)。在这里研究的化合物中,在使用NG108-15神经母细胞瘤-胶质瘤杂交细胞和/或大鼠脑膜制剂的试验中,只有先前报道的异硫氰酸根合化合物(10c)和(甲氧基富马酰基)氨基化合物(8c)分别与μ或δ阿片受体不可逆且选择性地相互作用。发现8c和10c在大鼠脑膜中与κ阿片位点在一定程度上不可逆地相互作用,其中μ和δ阿片受体通过与μ选择性不可逆配体BIT和δ选择性不可逆配体FIT相互作用而被耗尽。在电刺激的小鼠输精管制剂中,这两种化合物均未显示不可逆作用。